Full text is available at the source.
Abstract
Tirzepatide has demonstrated significant reductions in apnea-hypopnea index (AHI) among patients with obstructive sleep apnea and obesity.
- Tirzepatide is the first medication approved by the FDA specifically for moderate-to-severe obstructive sleep apnea in adults with obesity.
- In addition to improving sleep apnea outcomes, tirzepatide is associated with weight loss.
- The medication may also reduce cardiovascular, liver, and kidney events.
- Tirzepatide could represent a promising therapy for obstructive sleep apnea, potentially offering benefits beyond traditional treatments.
Simplified